Therefore, targeting the CCL22-CCR4 axis by the anti-CCR4 antibody mogamulizumab or the CCR4 inhibitor AZD2098 is being tested as a promising strategy of cancer immunotherapy (83, 84). This evidence concerns the gene CCR4 and cancer.